CATALYST PHARMACEUTICALS INC. - COMMON STOCK

Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023

23 Oct 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer

19 Oct 2023 08:03:00 By Nasdaq GlobeNewswire

Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida

16 Oct 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®

13 Oct 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference

18 Sep 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

16 Aug 2023 10:56:47 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress

14 Aug 2023 08:05:10 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

09 Aug 2023 16:17:05 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

19 Jul 2023 06:00:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

20 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023

01 Jun 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

30 May 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year

10 May 2023 16:28:05 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day

09 May 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report

01 May 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023

24 Apr 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting

20 Apr 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

15 Mar 2023 16:11:45 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies

08 Mar 2023 11:20:58 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023

01 Mar 2023 08:03:00 By Nasdaq GlobeNewswire